News - July 19, 2024
EUCOPE congratulates Ursula von der Leyen on her second mandate as President of the European Commission
EUCOPE congratulates Ursula von der Leyen on the confirmation of her second term as President of the European Commission. Her leadership and commitment to public health have been instrumental in steering Europe through challenging times. It is now fundamental to build on these accomplishments, delivering on the European Health Union, and encouraging further innovation in the pharmaceutical sector.
“We extend our heartfelt congratulations to President Ursula von der Leyen on her reappointment.” said Alexander Natz, Secretary General EUCOPE. “Her commitment is vital in advancing healthcare across Europe, and we are eager to continue our collaboration with the European Commission to drive innovation, enhance regulatory frameworks, and ensure that all Europeans benefit from cutting-edge medical treatment.”
EUCOPE emphasises the importance of sustained investment in healthcare research and development (R&D), regulatory frameworks that encourage innovation, and predictable policies that ensure patients have timely access to cutting-edge treatments and therapies, especially in case of orphan medicinal products (OMPs) and advanced therapy medicinal products (ATMPs).
EUCOPE commends the European Commission’s objective of making the EU a global leader in innovation. Building a competitive pharmaceutical industry environment is crucial, as it drives economic growth and job creation while also delivering significant societal benefits by improving health outcomes for patients.
The proposal for a new European Biotech Act may provide a pivotal tool to achieve a robust industrial framework that underpins and supports proliferation of European small and mid-sized biotech companies. Only by promoting innovative therapies such as ATMPs can we ensure that the EU remains at the forefront of medical advancements.
EUCOPE is committed to playing an active role in the policy-making process and collaborating with the European Commission, under the second Presidency term of Ursula von der Leyen, by providing expertise and insights to help shape a healthcare ecosystem that is fit for the future, championing the efforts of small and mid-sized pharmaceutical companies.
For more information, please contact: etevenot@eucope.org